HCC patients with tumors with high ERO1α expression had decreased 5-year OS and shorter recurrence-free survival (RFS) than patients with tumors with low ERO1α expression (P = 0.009, Fig. 2a; P = 0.005, Fig. 2b), consistent with that in TCGA database (Fig.S1C). This evidence concerns the gene ERO1A and hepatocellular carcinoma.